Objectives To determine the kinetics of alkaline phosphatase (AP) activity and concentration after infant cardiopulmonary bypass, including isoform-specific changes, and to measure the association between postoperative AP activity and major postoperative cardiovascular events, organ injury/dysfunction, and postoperative support requirements Study design Prospective cohort study of 120 infants ≤120 days of age undergoing cardiopulmonary bypass.
C ongenital cardiovascular defects are one of the most common birth defects (4-10 per 1000 live births). 1 Surgical repair often is required during infancy and despite improving mortality, the risk of death or transplant in the first year of life remains >25% for complex surgeries. 2 Postoperative morbidity is also a significant concern. Cardiopulmonary bypass (CPB), selective cerebral perfusion, and deep hypothermic circulatory arrest often are necessary for successful repair; however, these techniques independently result in global ischemia/reperfusion, inflammation, and organ injury/dysfunction. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Our understanding of these injury pathways is incomplete, and therapies to reduce postsurgical injury largely are limited to supportive care.
Alkaline phosphatase (AP), an endogenous metalloenzyme with multiple isoforms, recently has demonstrated beneficial physiologic activities in vitro. These activities include dephosphorylation of endotoxin to a less toxic monophosphoryl byproduct and conversion of harmful extracellular adenine nucleotides to adenosine. [19] [20] [21] Preclinical and phase 2 adult studies of AP therapy for sepsis and inflammatory colitis have shown a reduction in inflammation and organ injury. [22] [23] [24] AP also may be important after cardiothoracic surgery. AP activity decreases after cardiothoracic surgery in adults and children. [25] [26] [27] [28] In addition, low postoperative serum AP activity is associated independently with increased postoperative support requirements in infants. 28 However, significant gaps exist in our understanding of AP after infant cardiothoracic surgery, including the timing and persistence of decreased AP activity, isoform-specific changes, the balance of enzyme
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This study was designed to address these knowledge gaps. We hypothesized that loss of AP activity would begin during surgery and continue through the initial postoperative period. Activity of all AP isoforms would be affected equally and reflect decreased serum concentration rather than enzyme deactivation. We further hypothesized that early low AP activity would be associated with subsequent increased odds of a major cardiovascular event, increased postoperative support requirements, and increased evidence of renal, intestinal, and cardiac injury/dysfunction.
Methods
Our study was a prospective, observational cohort study of infants ≤120 days of age undergoing cardiothoracic surgery with CPB at Children's Hospital Colorado (Aurora, Colorado) between September 2013 and February 2016. Exclusion criteria were weight <2 kg (limited blood volume) and adjusted gestational age <34 weeks (altered AP production). 29 The protocol was approved by the Colorado Multiple Institutional Review Board, and informed consent from subject parents was obtained before enrollment. The study held to all ethical standards as dictated by Children's Hospital Colorado, the University of Colorado, Denver, the Colorado Multiple Institutional Review Board, and the Code of Ethics of the World Medical Association.
The primary study aims were to define the postoperative kinetics of AP, assess the correlation of AP activity to AP concentration, and determine whether low postoperative AP activity is associated with an increased risk of cardiac arrest, mechanical circulatory support, or death. Low postoperative AP was defined a priori as ≤80 U/L based on a potential threshold effect seen in our previously published data. 28 Secondary aims included assessment of isoform-specific AP changes, validation of the association between AP activity and postoperative support requirements, and measurement of the association between AP activity and organ injury/dysfunction.
We obtained baseline clinical information from all subjects (Table I) . Serum samples were obtained preoperatively, with rewarming from CPB, and at 6, 24, 48, and 72 hours after arrival in the cardiac intensive care unit (CICU). The 48-hour sample was not performed in subjects ≤3 kg to limit blood draw volumes. Also, to minimize discomfort, the protocol did not allow venipuncture. Therefore, no additional samples were obtained after removal of indwelling catheters.
Samples for AP activity were frozen to −70°C; total and isoform-specific AP activity were analyzed with commercially available assays (Mayo Laboratories, Rochester, Minnesota). Total AP activity was measured with a standard photometric p-nitrophenol phosphate cleavage assay. AP cleaves p-nitrophenol phosphate to yield phosphate and n-nitrophenol. The rate of p-nitrophenol production (determined photometrically at 450 nm) is directly proportional to AP activity. Isoforms were separated with the use of electrophoresis with additional isoform sialylation to achieve separation between liver and bone isoforms. Isoform activity was then determined with the specific chromogenic substrate, 5-bromo-4 chloro-3-indolyl phosphate/nitro blue tetrazolium in combination with densitometric quantification.
AP concentration and organ-specific injury/functional biomarkers were measured through 24 hours by the use of multiplex immunoassays (Meso Scale Diagnostics, Gaithersburg, Maryland). Biomarkers included N-terminal pro b-type natriuretic peptide (NT-proBNP-cardiac function), intestinal fatty acid binding protein (iFABP-enterocyte injury), and neutrophil gelatinase-associated lipocalin (NGAL-proximal renal tubule injury). We also recorded peak creatinine and lactate from postoperative measurements obtained as standard of care.
The primary clinical outcome was occurrence of any of the following major cardiovascular events: (1) cardiac arrest, (2) unplanned postoperative mechanical circulatory support, or 
Statistical Analyses
Subjects' baseline characteristics were summarized by the use of descriptive statistics. Correlation between AP activity and concentration was assessed by the Spearman correlation test. Spearman correlation test was performed to select candidate predictors for multivariable modeling. Distributions of continuous outcomes were inspected before modeling; natural log transformation was applied as indicated. General linear models were used for log-transformed outcomes and logistic regression models for dichotomized outcomes. Initial potential covariates were selected based on clinical or biological significance. Covariates that were significantly associated with both the primary explanatory variable and the outcome on univariate analysis were included in the initial model. Backwards stepwise regression was used to arrive at the final model. P value < .05 was considered statistically significant. SAS V9.4 (SAS Institute, Cary, North Carolina) was used for data management and analyses; GraphPad Prism 6 (GraphPad Software, La Jolla, California) was used for graphics.
Results
One hundred twenty-two subjects were enrolled in the study. Two subjects were converted to nonbypass surgery after enrollment and excluded. Subjects 1-100 were enrolled consecutively from the first 120 eligible patients (83% enrollment rate; Table II ; available at www.jpeds.com). The final 22 subjects were enrolled from eligible morning surgeries only to allow processing time for pilot laboratory tests. Baseline clinical and surgical data are presented in Table I .
AP activity was obtained in 98.8% of possible time points through 24 hours postoperation (Table III; available at www.jpeds.com). Median AP activity through 72 hours postoperation is shown in Table IV . AP activity decreased substantially between the preoperative and rewarming samples (median decrease 89 U/L; P < .0001). AP activity continued to decrease in 61% of subjects between rewarming and 6 hours, and 27% demonstrated a further decline between 6 and 24 hours. Low AP activity (≤80 U/L) was found in 5% of infants preoperation, 30% at rewarming, 40% at 6 hours, and 34% at 24 hours. A comparison of baseline characteristics for infants with AP activity ≤80 U/L vs >80 U/L at the rewarming time point is presented in Table I . After 24 hours, AP activity increased consistently, with only rare exceptions. The mean increase between 24 and 72 hours was 26.9 U/L (P < .0001). This change likely underestimates the increase for the whole cohort as we did not obtain 72-hour levels in a subset of healthier infants who no longer had indwelling catheters (Table V; available at www.jpeds.com). Sixteen infants demonstrated AP activity ≤80 U/L at 72 hours. Only a minority of infants (9%) regained preoperative activity levels by 72 hours.
Isoform-specific activity is shown in the Figure. Bone and liver 2 isoforms represented the clear majority of AP before surgery. Bone and liver 2 AP activities decreased between preoperation and rewarming, were stable to slightly decreased by 6 hours, and started slowly increasing by 24 hours. Intestinal AP activity doubled between preoperative and rewarming samples but remained a small portion of total AP activity. The liver 1 isoform increased markedly and constituted 17% of total AP activity at rewarming. Liver 1 activity was maintained through 6 hours then subsequently declined.
Serum AP activity and concentration were compared to assess whether changes in AP activity could be attributed primarily to decreased AP concentration. AP concentrations declined from preoperation to rewarming and then gradually increased after 24 hours. Activity and concentration were strongly correlated (r = 0.87-0.91; P < .0001), suggesting protein loss rather than enzyme dysfunction as the primary cause of diminished AP activity.
Our primary clinical outcome was the odds of a major cardiovascular event in subjects with AP activity ≤80 U/L. Eleven subjects experienced a major cardiovascular event (9%). Eight subjects experienced early cardiac arrest or need for mechanical circulatory support, and 3 died after progressive decline in hospital weeks to months after surgery. Early major cardiac events occurred exclusively in subjects with an AP activity of ≤80 U/L. Conversely, the 3 subjects with late postoperative death maintained AP levels >80 U/L at least through the 72-hour time point.
On univariate analysis, subjects with low AP activity at 6, 24, or 72 hours demonstrated increased odds of experiencing a major event (6-hour OR 4.4, P < .05; 24-hour OR 3.8, P < .05; 72-hour OR 8.7, P < .005). On multivariable analysis, low AP activity at 72 hours remained statistically significant (OR 5.6; P < .05), with the other time points demonstrating an OR of 2 but with CIs crossing 1. The absolute risk of a major event in subjects with a 72-hour AP activity ≤80 U/L was 30%. Univariate assessment of potential confounders and final multivariable models for all clinical outcomes are shown in Tables VI and VII (both available at www.jpeds.com).
Secondary clinical outcomes included postoperative VIS, length of intubation, and CICU/hospital LOS (Table VIII; available at www.jpeds.com). AP activity demonstrated an independent negative association with VIS at all time points on multivariable modeling. AP was associated most strongly with concurrent VIS. In our models, each 10 U/L decrease in AP at the 6-hour time point was associated with a 6% increase in VIS 6 hours (P < .0001), and for each 10 U/L decrease in AP at the 24-hour time point, VIS at 24 hours increased by 7% (P < .0001). Of note, AP activity at the rewarming time point (before the initiation of inotropic and vasoactive support) also was associated independently with subsequent VIS at 6 and 24 hours. AP activity at 24 hours was associated independently with length of intubation (4% increase in length of intubation for each 10 U/L decrease in AP; P < .05), with a similar trend for AP activity at 6 hours that did not reach statistical significance. AP activity was not independently associated with CICU or hospital LOS. Next, we assessed whether early AP activity (rewarming and 6 hours) was associated with biomarkers of organ perfusion, injury, and dysfunction. AP activity at 6 hours was associated with greater subsequent (24 hours) NT-proBNP and iFABP levels but not concurrent (6 hours) levels of these markers (Table IX) . AP activity at 6 hours also demonstrated a strong independent association with peak creatinine and peak lactate (Table IX) . AP activity at rewarming also showed a strong, independent negative association with peak creatinine and peak lactate but not NT-proBNP or iFABP (Table IX) . Surprisingly, we did not find an association between AP activity and NGAL. However, in our cohort, NGAL also showed no association with peak creatinine or change in creatinine, so it is unclear how well the biomarker performed in our specific population.
Discussion
Our key findings center on a significant early loss of AP activity that began before separation from bypass and was attributable to decreased concentrations of bone and liver 2 isoforms. Most subjects showed ongoing AP loss through 6 hours postoperation and nearly one-third experienced continued decline through 24 hours. Early low AP activity demonstrated a strong, independent association with subsequent cardiovascular support requirements, peak lactate, and peak creatinine. Early low AP activity also was associated with subsequent biomarkers of enterocyte injury and cardiac dysfunction. Recovery of AP activity typically began within 72 hours; however, only a small minority of subjects regained their preoperative AP activity by that time. Failure to increase AP activity >80 U/L by 72 hours was an ominous sign, with this subset of subjects demonstrating increased odds of a major cardiovascular event.
AP activity after CPB was first evaluated in 1974 by Neutze et al, 27 who described~50% decrease in AP activity in 9 children between preoperation and postoperative day 1. These findings subsequently were replicated by 2 adult studies 25, 26 and by our group in a larger cohort of infants. 28 Less is known about the timing of AP activity loss during this first 24 hours or its recovery following surgery. Kats et al 26 described decreasing AP activity over the first 2 hours of coronary artery bypass grafting followed by a recovery to baseline within 24 hours. In our cohort, most AP activity loss also occurred early. However, we found ongoing decreases through 6 and even 24 hours postoperation, indicating the process is not isolated to the operation. Also different from previous adult cohorts, AP activity in our infants remained well below preoperative levels through 72 hours, demonstrating a more profound deficiency and potentially slower resolution of the underlying mechanism.
The exact etiology of AP activity loss after cardiac surgery has yet to be defined. In the only study to directly assess this etiology, Lum et al 25 explored whether hypomagnesemia could explain the post-bypass decrease in AP activity because magnesium is a key cofactor for AP. Although serum AP activity and magnesium decreased simultaneously, ex vivo addition of magnesium failed to increase AP activity. Our study provides the first evidence that decreased AP activity is secondary to decreased serum concentration. Several possible reasons exist to explain this decrease in AP concentration. Lum et al 25 examined the role of hemodilution but did not identify any correlation between AP activity and total protein levels, a finding we have previously replicated. 28 Filtration is also unlikely as AP is larger than the filtration size of our circuit and AP activity decreases in some cases of off-bypass infant cardiac surgery. 28 Decreased production of AP has been proposed; however, patients receiving a systemic infusion of bovine intestinal AP during CPB demonstrated preservation of native AP activity, a finding more consistent with consumption than decreased production. 26 A consumptive process also is supported by animal models suggesting AP targets endotoxin released during intestinal ischemia-reperfusion, forming a conjugate that subsequently is cleared by Kupffer cells in the liver. 32 Isoform-specific changes lend additional insight. Previous studies documented decreases in bone AP in multiple settings including neonatal infection, 33 low cardiac output in patients undergoing the Fontan procedure, 34 and coronary artery bypass grafting. 26 These changes were thought to reflect decreased osteoblast activity, although other AP isoforms were not measured. Our findings demonstrate a proportional decrease in bone and liver 2 isoforms during infant cardiac surgery. This proportional decrease suggests either decreased production of both isoforms or more likely a consumptive process. In contrast, liver 1 and intestinal isoforms were not detectable preoperation but increased postoperatively. The increase in serum intestinal AP is not surprising; previous studies have identified intestinal brush border proteins in the serum after cardiac surgery. 35 The reason for the immediate postoperative increase in liver 1 AP is less clear. Muraoka et al 36 reported a similar finding in healthy liver donors. They hypothesized these changes were related to liver regeneration, and it is possible that a similar physiology occurs following ischemia-reperfusion of the liver in our population.
From a clinical standpoint, AP decreased before separation from bypass, temporally preceding key short-term clinical outcomes. Early low AP activity was associated strongly with subsequent cardiovascular instability and poor oxygen delivery, as evidenced by greater VIS and peak lactate levels. The worst cases of cardiovascular instability (postoperative cardiac arrest or unplanned mechanical circulatory support requirement) were preceded uniformly by low AP activity, and persistently low AP activity at 72 hours was associated with increased odds of experiencing a major cardiovascular event. Low AP activity also was associated with and temporally preceded biomarker evidence of renal, enterocyte, and cardiac injury/dysfunction. Interestingly, low AP activity was not associated with CICU LOS, hospital LOS, or late death in hospital, indicating that the associations we observed were limited to the early postoperative period.
Our study supports at minimum the potential clinical utility of AP as a novel biomarker of postoperative perfusion, renal dysfunction, intestinal injury, and cardiac arrest/need for mechanical circulatory support. The finding that low AP activity already is present before separation from bypass increases its potential impact, as it may provide very early risk stratification both for clinical and research purposes. The strong association with postoperative renal dysfunction was particularly interesting, given the interest in development of early biomarkers for acute kidney injury; AP significantly outperformed NGAL for this purpose in our cohort. In addition to possible use as a prognostic biomarker, our findings provide preliminary evidence for the use of AP as a biomarker of response to therapy in the early postoperative period. Low AP demonstrated a progressively stronger association with cardiovascular support requirements and length of mechanical ventilation through the first 24 hours postoperation, and persistence of low AP activity at 72 hours was associated with markedly increased odds and absolute risk of cardiac arrest or need for mechanical circulatory support. Further study is warranted to assess whether AP trend could be used to monitor recovery and serve as an adjunct biomarker to identify high risk patients requiring escalation of therapy.
Although development of AP as a biomarker is intriguing, its greater potential may be as a therapeutic target. It has been proposed that AP could be protective after ischemia-reperfusion injury and other inflammatory processes through the dephosphorylation of toxic phosphate-containing molecules in a number of pathologies. [22] [23] [24] Two proposed targets of AP, endotoxin 18, 32, 37 and extracellular adenine nucleotides, 20, 38, 39 are released following ischemia-reperfusion injury and can lead to cardiovascular instability, tissue injury, and inflammation. We previously identified a decrease in serum capacity to convert extracellular adenosine monophosphate to adenosine in the immediate postoperative period that is directly related to serum AP activity. 21 Ex vivo addition of liver AP markedly improved this capacity. It is possible that decreased AP activity could result in poor clearance of endotoxin and/or extracellular adenine nucleotides leading to subsequent inflammation and cardiovascular instability. Two phase 2 trials in adult sepsis 22, 23 and 1 in adult ulcerative colitis 24 have used AP therapy November 2017
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with promising early results on kidney function and intestinal inflammation respectively. The fact that cardiac surgery provides a predictably timed physiologic insult and AP activity declines early in the perioperative course makes therapeutic intervention particularly attractive in this setting. Recently, a phase 2 study of bovine intestinal AP infusion during adult coronary artery bypass grafting demonstrated decreased inflammation in this low-risk patient population, supporting the idea that this treatment is feasible and may have clinical efficacy for cardiac surgery patients. 40 Our study has several limitations. This cohort was recruited from a single institution. Although multiple studies have demonstrated a decrease in AP activity after cardiac surgery, specific findings from our study may not be generalizable to other centers, particularly those that use different perfusion and filtration techniques. As with all observational studies, we cannot differentiate between associations and causal relationships. Animal models and human clinical trials will ultimately be needed to assess any direct role of AP in modulating postcardiac surgery cardiovascular stability, organ injury, and outcomes. Our study focuses on soluble AP. AP is also present in many different organs at the cellular/tissue level, 41 and future studies, including animal models, should assess the role of tissue-based AP in organ protection after infant cardiac surgery. Finally, due to the restrictions of blood volume we were limited in the number of tests we could analyze. Additional analysis of intraoperative time points could improve our understanding of AP loss in this population.
AP activity decreases markedly during infant cardiac surgery with CPB and may continue to decrease through 24 hours postoperation. Activity loss is secondary to decreased bone and liver 2 isoform concentrations. Early low AP activity is associated independently with subsequent increased postoperative support and organ injury/dysfunction, and persistence of AP ≤80 U/L at 72 hours is associated independently with increased odds of cardiac arrest, mechanical circulatory support, or death. ■ 
